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In 2016 the Psychoactive Substances Bill banned trading but
not possession of all current and future novel psychoactive
substances (NPS), sometimes incorrectly called “legal highs,”
in an attempt to overcome rapid proliferation of these
compounds. Over 560 substances are currently monitored by
the EuropeanMonitoring Centre for Drugs and Drug Addiction,
with 100 new agents identified in 2015 alone. Stimulants and
synthetic cannabinoids account for the vast majority and are the
types most commonly clinically encountered.1Online purchases
are increasing according to the 2016 Global Drug Survey,2
potentially in response to legislative changes, as is overall NPS
use: lifetime consumption was reported by 8% of younger
individuals in 2015, up from 5% in 2011, with figures relatively
similar between sexes and different countries.3
Professionals report feeling less confident about managing NPS
compared with established recreational drugs.4 There were 15
485 accesses to UK National Poisons Information Service
TOXBASE relating to “legal highs,” “branded products,”
synthetic cannabinoids, andmephedrone in 2014-15.5Regarding
harms from longer term dependence, the UK National Drug
Treatment Monitoring System (NDTMS) report in 2015
described 3048 and 1370 adults with documented problematic
use of mephedrone and “other” NPS respectively.6
Information on NPS primarily stems from case reports and case
series. However, there is evidence that risks associated with
NPS are often different from those seen with established
recreational drugs. This article classifies NPS into their major
groupings and provides information on the desired effects of
these compounds, their pharmacology, and the risks associated
with their use. The linked Practice article7 provides advice on
what to ask and do when consulting with a patient who may be
using NPS.
What are NPS and how do they work?
NPS are compounds designed to mimic existing established
recreational drugs such as “ecstasy” (MDMA) and cannabis.
Before changes in the law, manufacturers would tweak the
pharmacological structure of existing compounds to create a
new “legal” substance, which earned them their familiar name
“legal highs.” There is no universally agreed way to categorise
NPS. However, they can be broken down into four, somewhat
overlapping, main categories: stimulants, cannabinoids,
hallucinogens, and depressants.
Stimulant NPS (fig 1)
Stimulants are taken to produce a sense of euphoria and
wellbeing, or “a high.” This is one of the largest NPS groups,
typically sold as powders or pills. Mephedrone is the most
commonly available variant. They are structurally related to
MDMA (ecstasy), cocaine, and amphetamines and can be
swallowed (users often talk about “bombing,” when the drugs
are swallowed wrapped in paper), inhaled (“snorting”), and,
less commonly, injected or administered rectally.
Stimulants increase synaptic levels of serotonin, dopamine,
and/or noradrenaline. Agents act as neuronal reuptake pump
inhibitors or as active releasers, and each has an unique effect
on neurotransmitter concentrations.8 9Neurotransmitter releasers
are associated with greater addiction and neurotoxicity.10 11NPS
variants, such as the large cathinone family, are commonly
associated with enhanced neurotoxicity compared with
traditional stimulants.9 12
The ratio of serotonin to dopamine activation is important in
achieving the desired effects. The more serotonergic drugs,
similar to ecstasy, produce more empathy and emotional
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What you need to know
• Novel psychoactive substances (NPS, “legal highs”) are compounds designed to mimic existing established recreational drugs. They
can be grouped into four main categories: stimulants, cannabinoids, hallucinogens, and depressants
• Legislation regarding NPS varies internationally. In the UK it is now illegal to distribute or sell NPS, but possession is not a criminal
offence
• NPS should not be regarded as safer than established recreational drugs
• The most commonly clinically encountered NPS are stimulants (such as mephedrone) and cannabinoids (such as “spice”)
• Psychiatric and rehabilitation units, prisons, and schools face particular challenges in detecting and preventing use
Sources and selection criteria
• We searched Medline and Embase for publications using the terms “legal highs,” “NPS,” and “novel psychoactive substances”
• The subject is challenging to appraise: there is a dearth of information on the hundreds of new compounds, much being case based reports;
drug effects are inherently subjective, and it can be complex to engage drug consumers in an area concerning quasi-illegal behaviour. Where
possible, systematic reviews were consulted.
• Much of the information on the topic is in non-scientific publications such as governmental and other agencies’ reports, including from the
European Monitoring Centre for Drugs and Drug Addiction, “grey” non-peer reviewed sources such as the Global Drug Survey, and on user
discussion forums such as Erowid.
openness.13 14 More dopaminergic drugs, similar to cocaine,
produce more euphoric and mania-like experiences.15 Some
NPS stimulants, such as the NBOMe- and 2C-series, also
produce psychedelic or hallucinogenic experiences.16 17
Risks
Acute adverse presentations are most commonly associated with
agitation, anxiety, psychotic symptoms, hypervigilance,
cardiovascular toxicity (arrhythmias and hypertension), and
hyperthermia. Case reports also describe seizures, delirium, and
renal and respiratory failure following ingestion.18-21 Serotonin
syndrome—autonomic instability, confusion, and neuromuscular
problems—can be life threatening and is particularly associated
with use of multiple serotonergic recreational drugs, or
concomitant use of serotonergic prescription medication or over
the counter medicines such as St John’s wort.15 22
Long term, traditional stimulants are associated with impulsive
behaviour, abuse, and dependency,15 and NPS stimulants seem
no different.23 Depression and cognitive impairments are
recognised sequelae,24 and there are case reports of
psychoses.25 26Cessation can lead to a psychological withdrawal
syndrome of fatigue, insomnia, lethargy, flu-like symptoms,
impaired concentration, and lability of mood.23 There is
considerable variation between individuals, but such outcomes
are more commonly associated with longer term and more
regular drug use.
Cannabinoid NPS (fig 2)
Cannabis is the most widely used established recreational drug.1
NPS variants are the synthetic cannabinoid receptor agonists
(SCRAs), and there are over 150 different SCRAs available,
usually sold having been sprayed onto herbal mixtures that are
smoked. They are sometimes referred to as “spice” or “noids.”
Liquid SCRAs also exist for use in electronic cigarettes and
vapourisers. They produce a pleasant state of relaxation and of
feeling “stoned.”
The major psychoactive component of cannabis is
tetrahydrocannabinol, a partial agonist at cannabinoid receptors
that ordinarily have roles in neuronal homeostasis and immune
functioning.27 However, SCRAs are typically full agonists of,
and bind in a different pattern to, cannabinoid receptor subtypes.
SCRAs also lack cannabidiol, an antipsychotic and anxiolytic
compound found in cannabis that dampens some of the effects
of tetrahydrocannabinol. These pharmacological differences
may explain the variation in the subjective and physiological
effects of SCRAs compared with cannabis.28-30
Risks
As well as a subjective effect of feeling stoned, cannabis and
SCRAs can be both stimulating and sedating, anxiogenic and
anxiolytic.27 31 Both can cause anxiety, paranoia, and psychotic
symptoms.32 33
Side effects have been reported more frequently with SCRAs
than with cannabis,28 and, as they are most commonly sprayed
onto compounds for smoking, their strength and effects can be
less predictable. Some highly potent agents can induce
considerably agitated states.31Unlike cannabis, some produce a
“hangover” state.34 Emergency department case reports describe
additional features with SCRA use not typically seen with
cannabis, such as confusion and cognitive impairment, slurred
speech, and excessive sweating, as well as symptoms of
stimulant toxicity (hypertension, tachycardia),32 35 renal failure,
pulmonary damage, myocardial infarction, seizures, and
stroke.32-38
In the longer term, cannabis is not traditionally considered to
produce physical dependency, though individuals can
demonstrate a psychological dependency.39 Case reports and
user discussion forums suggest that SCRAs have a higher
potential for addiction and withdrawal effects.40-42
Hallucinogenic NPS (fig 3)
Hallucinogens fall into two subcategories—dissociatives and
psychedelics (or classical hallucinogens). Dissociatives are
particularly associated with harmful side effects.
Dissociatives
Dissociatives produce a unique euphoric “dissociated” state,
with a perception of an absence of time, weightlessness, and
disconnection from the physical body. They can be inhaled,
swallowed, or injected. The first agents in this class, ketamine
and phencyclidine (PCP), were originally used as general
anaesthetics, but they have generally been discontinued because
of postoperative dissociative side effects. The spectrum of NPS
dissociatives runs between somemilder than ketamine to others
as strong as phencyclidine.10 The common variant
methoxetamine (sometimes called “mexxy”) is generally
reported to produce more intense and longer lasting dissociative
effects than ketamine.43 In extremis, users may enter an “m hole”
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(similar to a “k hole” with ketamine), a state of profound
dissociation that some people find highly pleasurable and others
unpleasant.10-47 They primarily act as uncompetitive antagonists
at glutamatergic NMDA receptors,48 but also bind at opioid and
monoaminergic receptors.10
Risks
Most risk data come from the parent compounds ketamine and
phencyclidine, though the evidence emerging from NPS case
studies literature fits with these.46 47 Deaths are primarily
accidental, through impulsive and careless behaviours,10 although
there are reports of fatalities directly linked to methoxetamine
toxicity.49 50 Consistent with ketamine and phencyclidine, there
are case reports of aggressive, psychotic, and catatonic states
with dissociative NPS use, acute cerebellar toxicity,
cardiovascular incidents, and renal and acute respiratory
failure.10-51Methoxetamine was anecdotally sold as a physically
safer alternative to ketamine, but there is limited evidence to
support this currently.50
Longer term, dissociatives often produce considerable cravings
and binge consumption patterns, although there is some evidence
that methoxetaminemay be less addictive than ketamine.50 Long
term sequelae of use can include neurocognitive deficits and
deterioration in mood.52 53 Physical health complications include
abdominal pain (“M cramps”), nausea, vomiting, and diarrhoea;
cardiovascular problems of arrhythmias and blackouts10; and
severe ulcerative cystitis and renal damage.54
Psychedelics
These agents typically do not produce true hallucinations, but
are associated with a range of “psychedelic” effects, including
perceptual alterations and quasi-mystical experiences sometimes
categorised under the headings of “oceanic boundlessness” and
“anxious ego dissolution.”55 56
These exert their effects primarily as an agonist at the 5-HT2A
receptor. There is some evidence they may also act on 5-HT1A
and heteromer receptor complexes.56 Traditional agents include
LSD and psilocybin; most NPS psychedelics, such as
5-MeO-DALT and the NBOMe- or 2C-series, also have
stimulant effects.10-58
Risks
Psychedelics generally have a low risk-profile compared with
both other established recreational drugs and NPS. Consumers
seldom present acutely to clinical services, though acute
intoxication may contribute to adverse mood reactions.56Unlike
established recreational psychedelics, someNPS hallucinogens
also have stimulant properties, and these have increased risk of
acute toxicity, including agitation, hallucinations, tachycardia,
hypertension, hyperthermia, rhabdomyolysis, serotonin
syndrome, and seizures.57-61 There is currently little evidence of
longer term health risks or addiction.56
Depressant NPS (fig 4)
Depressant NPS subcategories—benzodiazepines and
opioids—seem to carry a similar picture for acute emergency
presentations but differ in their mental health implications. They
are generally sold and consumed in pill or powder form. They
are perhaps the least understood of the NPS. This may be
because they are so similar to established recreational drugs that
clinicians may not be aware that an individual has used an NPS
version. NPS benzodiazepines include diclazepam and
flubromazepam. Fewer NPS opioids have appeared in isolation,
but they may be sold as part of NPS cannabinoid smoking
mixtures, as has been reported for AH-7921.62
Benzodiazepines
These are positive allosteric modulators of the GABA receptor,
enhancing inhibitory signalling in the central nervous system.10
Alcohol has a similar pharmacodynamic mechanism and can
potentiate their effects.10 Acutely, NPS benzodiazepines have
similar clinical effects to established compounds such as
diazepam,with sedative, anxiolytic, hypnotic, and anticonvulsant
properties. Some users of NPS benzodiazepines report that they
have much longer durations of actions and effects than
established agents, and several compounds have long half lives
(flubromazepam, for example, having a half life of 100 hours63).
While this reduces dependency potential, unwanted effects can
persist for a long time and there are greater risks of accidental
overdose. There are reports of NPS benzodiazepine induced
confusional states lasting several days.64Acute withdrawal may
cause seizures.65 Long term use is associated with risk of
addiction and impaired cognition,66 physiological and mental
health sequelae consistent with traditional benzodiazepines.65
Opioid NPS
Little is known about any specific subjective effects of NPS
opioids to differentiate them from established recreational
opioids. However, self experimentation reports suggest that
some can have much longer durations of action.67 68 They exert
their euphoric effects through presynaptic μ-opioid receptors.
Novel agents such as AH-7921, MT-45, and novel fentanyls
seem to have similar mechanisms of action.67 69
Case reports of NPS overdoses are congruent with those of
traditional opioids, though animal data suggest AH-7921 has a
higher overdose risk than morphine.67 Both human case series
and animal studies have shown that naloxone can reverse the
toxicity seen with novel opioids, although the doses of naloxone
required may be higher than for traditional opioids, particularly
in cases of novel fentanyl toxicity.67-71 There have been reports
of unusual toxicity related to the use of MT-45, including
short-to-medium term hearing loss.71
No long term NPS risk data exist, though animal models have
shownAH-7921 to be similar to morphine in addictive potential
and withdrawal effects,67 and MT-45 and novel fentanyls are
probably similar.
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Priorities for future research
• More robust data on epidemiology and links to acute and long term harms
• Evaluating the demands and effectiveness of existing drug treatment services to manage harmful or problematic NPS use
• Long term development of pharmacological treatments for dependency: currently only available for opioids and benzodiazepines,
though there is work on cannabinoid and stimulant agents
• Determining any adverse neurodevelopmental impact on younger users
Information for patients who ask about NPS
• In the UK the Psychoactive Substances Bill states that individuals will be prosecuted for trading, but not possession, of NPS. It is
uncertain how monitoring and enforcing will work in practice, but one effect is that supply chains will move away from high street “head
shops”
• NPS do not seem to be safer or less harmful than established recreational drugs, either in the short or longer term, though there is
considerable variation in risks between individual NPS and classes of NPS
• If using a novel substance, as with any drug, start with a very small dose and increase if necessary to obtain desired effects
• Individuals can have very different responses to the same drug, and combining with other recreational, prescription, or over the counter
drugs or alcohol can increase risks
• Seek urgent medical help if you or a friend feel unwell after using a NPS (as with any recreational drug). Call 999 for an ambulance;
take the compound or any information on it with you if possible
Resources for healthcare professionals
• UK National Poisons Information Service (www.npis.org) and its clinical toxicology database TOXBASE (www.toxbase.org)—If you
need advice or information that is not available on TOXBASE then call NPIS for clinical support
• NEPTUNE (novel psychoactive treatment: UK network) (http://neptune-clinical-guidance.co.uk)—Comprehensive clinical guidance
on party drugs
• Wood DM, Dargan PI. Understanding how data triangulation identifies acute toxicity of novel psychoactive drugs. J Med Toxicol
2012;8:300-3
• Baumeister D, Tojo LM, Tracy DK. Legal highs: staying on top of the flood of novel psychoactive substances. Ther Adv Psychopharmacol
2015;5:97-132—Review of the neurobiology of NPS
• GOV.UK. New Psychoactive Substances (NPS) resource pack (www.gov.uk/government/publications/new-psychoactive-substances-
nps-resource-pack)—UK Home Office NPS resource pack for “informal educators and frontline practitioners”
• EMCDDA. EU drug markets report (www.emcdda.europa.eu/start/2016/drug-markets)—Guide to the European illicit drugs’ market
Resources for drug consumers and the public
• FRANK (friendly confidential drugs advice). Legal highs (www.talktofrank.com/legalhighs)—UK based general information guide for
patients and the lay public
• EROWID (www.erowid.org)—Non-profit, international, drug-consumer-led website providing non-judgmental advice and guidance
• Rise Above (http://riseabove.org.uk/tag/drinking-smoking-drugs/)—Website by NHS England for children and adolescents about
substance misuse, mental health, and other social issues
• Bowden-Jones O. The Drug Conversation: How to talk to your child about drugs. Royal College of Psychiatrists, 2016
• Global Drug Survey (www.globaldrugsurvey.com)—Information for, and international survey of, NPS consumers
• Sumnall H, Atkinson A. The new Psychoactive Substances Bill–a quick introduction. (www.cph.org.uk/blog/the-new-psychoactive-
substances-bill-a-quick-introduction/)—Guide to legislative changes in the UK
How patients were involved in the production of this article
A patient with long term harmful use of NPS, including significant associated mental ill health, was involved in the initial design of this article.
This particularly helped frame the discussion on the potential harms of these compounds. The patient wishes to remain anonymous.
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Fig 1 Visual summary of stimulant NPS
Fig 2 Visual summary of cannabinoid NPS
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2017;356:i6848 doi: 10.1136/bmj.i6848 (Published 25 January 2017) Page 7 of 8
PRACTICE
Fig 3 Visual summary of hallucinogenic NPS
Fig 4 Visual summary of depressant NPS
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